Adolescents were studied directly
STEP TEENS randomized 201 adolescents aged 12 to under 18 to weekly semaglutide 2.4 mg or placebo with lifestyle intervention for 68 weeks. All but one participant had obesity. The primary outcome was percentage change in body mass index, or BMI, rather than the adult-trial headline of percentage weight change. [1]
The outcome label is essential. BMI change and weight change are not interchangeable figures, especially when interpreting a study in growing young people. Repeating the number without its measure can make a pediatric result look directly comparable with an adult weight-loss percentage when it is not.
Results and safety findings
Average BMI change was −16.1% with semaglutide and +0.6% with placebo. Gastrointestinal adverse events occurred in 62% versus 42%. Gallstones were reported in five semaglutide participants and none receiving placebo. Serious adverse events occurred in 11% and 9%. Novo Nordisk funded the study. [1]
A balanced summary keeps those safety findings visible rather than presenting only the primary result. A small study also cannot settle every uncommon or longer-term concern. The result needs interpretation within pediatric care, including the broader circumstances of the young person.
What cannot be borrowed from adult services
An adolescent trial does not establish that an adult telehealth membership accepts minors or provides appropriate pediatric follow-up. Provider eligibility and clinical capability are separate facts that must be checked directly. Adult comparison pages should not be treated as a referral pathway for a child.
The paper also should not be used to set a teenager a cosmetic weight target. It studied a defined medical population under a research protocol. Discussion of relevance belongs with clinicians experienced in adolescent care and should consider health, development and support rather than a promotional before-and-after narrative.
For contrast in how adult evidence is framed, STEP 2 uses an adult diabetes population and a weight endpoint. That contrast is methodological only; adult findings should not be used as pediatric treatment instructions.
Questions for a family’s clinical discussion
Ask how the clinician interprets BMI over time, which outcomes are important beyond that measure and what follow-up involves. Clarify how the young person’s questions and preferences will be included. The purpose of reading the research is to support an informed conversation, not to create pressure to match a trial average.
Our trial-reading guide explains the general distinction between participants, comparator and endpoint. For this topic, keep the clinical discussion within qualified adolescent care. The adult services elsewhere on this site have their own eligibility rules; this research article makes no claim that any listed provider treats children or teenagers.